Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The US experience

Dermatologic Surgery

Volumn 32, Issue 11, 2006, Pages 1336-1345

  Mest, Douglas R ^a,b   Humble, Gail ^a,b  

^a Blue Pacific Aesthetic Medical Group   (United States)

^b Dermik Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYLACTIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMMON COLD SYMPTOM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PAPULE; PATIENT SATISFACTION; PHOTOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; SINUSITIS; SKIN BRUISING; SKIN REDNESS; SKINFOLD THICKNESS; SWELLING; VOMITING; WELLBEING;

ADULT; AGED; BIOCOMPATIBLE MATERIALS; COSMETIC TECHNIQUES; FACE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS, SUBCUTANEOUS; LACTIC ACID; MIDDLE AGED; PATIENT SATISFACTION; POLYMERS; TREATMENT OUTCOME;

EID: 33750609380     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2006.32303.x     Document Type: Article

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
2. Miller J, Carr A, Emery S, et al. HIV Lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003;4:293-301.
3. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipdaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
4. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. J AIDS 2003;32:48-56.
5. Mallon P, Miller J, Cooper D, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003;17:971-9.
6. Carrieri P, Cailleton V, Le Mong V, et al. The dynamic of adherence to highly active anitretroviral therapy: results from the French National APROCO cohort. J AIDS 2001;28:232-9.
7. Power P, Tate HL, McGill SM, Taylor C. A qualitative study of the psychological implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect 2003;79:137-41.
8. Martinez E, Garcia-Viejo MA, Blanch L, Gotell JM. Lipodystrophy syndrome in patients with HIV disease: quality of life issues. Drug Saf 2001;24:157-66.
9. Duckers NH, Stolte IG, Albrecht N, et al. The impact of experiencing lipodystrophy on the sexual behavior and wellbeing among HIV-infected homosexual men. AIDS 2001;15:812-3.
10. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS 2001;15:2441-4.
11. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000;14:2857-67.
12. James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002;28:979-86.
13. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003;17:2471-7.
14. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004;5:82-7.
15. Mest DR, Humble G. Safety and efficacy of intradermal implants of poly-L-lactic acid (Sculptra) in persons with HIV-associated lipoatrophy. Antivir Ther 2004;L36.
16. Armard P, Saint-Marc T, Katz P. The effects of polylactic acid (New-Fill) as therapy for Lipoatrophy of the face [abstract]. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; 2000 Sep 12-15; Toronto, Canada.
17. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2003;288:207-15.
18. Martin A, Smith D, Carr A, et al. Reversability of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study. AIDS 2004;18:1029-36.
19. Martin A, Mallon P. Therapeutic approaches to combating lipoatrophy: do they work? J Antimicrob Chemother 2005;55:612-5.
20. Lafaurie M, Dolivo M, Porcher R, et al. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J AIDS 2005;38:393-8.
21. Jones D, Carruthers A, Orentreich D, et al. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial. Dermatol Surg 2004;30:1279-86.
22. Orentreich D, Leone AS. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone. Dermatol Surg 2004;30:548-51.
23. Comite S, Liu JF, Balasubramanian S, et al. Treatment of HIV-associated lipoatrophy with Radiance FN™ (Radiesse™). Dermatol Online J 2005;10:2.
24. Levan P, Nguyen TH, Lallemand F, et al. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS 2002;16:1985-7.
25. Olenius M. The first clinical study using a new biodegradable implant for the treatment of lips, wrinkles and folds. Aesthet Plast Surg 1998;22:97-101.
26. Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005;52:233-9.
27. Sculptra package insert. Berwyn (PA): Dermik Laboratories; 2004.
28. Engelhard P, Knies M. Safety and efficacy of New-Fills (polylactic acid) in the treatment of HIV-associated lipoatrophy of the face (HALF). XIV International AIDS Conference; 2002 Jul 7-12; Barcelona, Spain.
29. Woerle B, Hanke CW, Sattler Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol 2004;3:385-9.